Navigation Links
MRSA vaccine shows promise in mouse study

By combining the four bacterial surface proteins that generate the strongest immune response in mice, researchers at the University of Chicago have created a vaccine that significantly protects immunized animals from multiple disease-causing, drug-resistant strains of Staphylococcus aureus, the most common cause of hospital-acquired infections and a rapidly spreading source of community-associated illness.

The vaccine protected mice against potentially lethal infections with five virulent S. aureus strains, the researchers report in the Nov. 7, 2006, issue of the Proceedings of the National Academy of Sciences, available early online. These strains include USA100, a common cause of hospital-acquired infections, and USA400, a virulent community-associated strain that carries lung-damaging toxins. All five strains were resistant to most of the drugs used to treat S. aureus infections.

"This microbe's ability to acquire the tools it needs to protect itself from the drugs we use to treat it is legendary," said study director Olaf Schneewind, M.D., Ph.D., professor and chairman of microbiology at the University of Chicago, "which is why a vaccine has become such a high priority. One by one, this organism has learned how to evade nearly all of our current antibiotics. So, generating protective immunity against invasive S. aureus has become an important goal."

Previous vaccine attempts using killed or live attenuated bacteria, or selected bacterial subunits, produced, at best, only partial immunity. "For S. aureus vaccines to succeed," said Schneewind, "we need to stimulate an immune response that can recognize the specific cell-surface proteins responsible for virulence and can recognize them from multiple strains."

The researchers turned to a newer technique, known as "reverse vaccinology," recently used to develop candidate vaccines against group A and group B streptococci and group B meningococci. Access to the S. aureus genome
'"/>

Source:University of Chicago Medical Center


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MRSA vaccine shows promise mouse study

(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... 4, 2013 /Press Release/ Toxic waste sites with ... of "healthy years of life lost" in individuals living near ... a study by a Mount Sinai researcher published online today ... Kevin Chatham-Stephens, MD, Pediatric Environmental Health Fellow at the Icahn ...
... ON New research indicates that Mexican-Americans born in the ... significantly more likely than Mexican-American immigrants to report that ... physical activities such as walking, climbing stairs, reaching, lifting, ... in this week,s International Journal of Environmental Research ...
... 2, 2013 CDX Diagnostics, Inc ("CDX") and Shared ... patent infringement action against Histologics, LLC, Poplar HealthCare, PLLC ... Avero Diagnostics (collectively, "Defendants") in the United States District ... York . According to court documents, CDX and ...
Cached Biology News:Toxic waste sites cause healthy years of life lost 2Older US-born Mexican-Americans more physically limited than Mexican-American immigrants: Study 2Shared Medical Resources, LLC files suit against Histologics, LLC, Women's Health Laboratories and Avero Diagnostics for Willful Patent Infringement 2
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... Calif. , April 23, 2015  Cryoport, ... advanced cryogenic logistics solutions for the life sciences ... established its cryogenic logistics solutions within the animal ... with Yancey Farms to support the shipment of ... German Sport horse Stallions. Animal ...
(Date:4/23/2015)... Glemser Technologies is ... Enterprise Content Division (ECD) Certified Solution Partner to ... for Life Sciences Solution Suite . The accreditation ... to provide life sciences companies of all sizes ... EMC Documentum Solution Suite offers four modules: Quality ...
(Date:4/23/2015)... April 23, 2015  Propanc Health Group Corporation ... focuses on the development of cancer treatments for ... lead product includes PRP, a patented formulation consisting ... as well as the enzyme amylase designed to ... a combination of anti-cancer agents working in combination ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
...
Biology Products: